moatshark My

All holdings

BioNTech

BNTX

Source: the SEC Form 13F filings of the managers we follow, latest for Q3 2026. How we use them

Managers holding
1
In their latest 13F (Q3 2026)
See who
Value held
$342m
Combined value at quarter end
Last quarter
1 bought
0 sold or trimmed
Fund portfolios
2
Funds holding it
See which
Price at Q2 ’26 end
$93.05
+4.7% in the quarter

Prices here are quarter-end prices implied by the 13F filings. Today’s price on Yahoo Finance

Share price change by quarter

-7.4%Q3 ’25
-3.5%Q4 ’25
-6.6%Q1 ’26
+4.7%Q2 ’26
Q3 ’25: -7.4%; Q4 ’25: -3.5%; Q1 ’26: -6.6%; Q2 ’26: +4.7%

Change in the quarter-end price implied by managers’ 13F filings, adjusted for stock splits. Excludes dividends.

Managers holding it, by quarter

0Q4 ’23
0Q1 ’24
0Q2 ’24
0Q3 ’24
0Q4 ’24
0Q1 ’25
1Q2 ’25
1Q3 ’25
1Q4 ’25
1Q1 ’26
1Q2 ’26
0Q3 ’26
Q4 ’23: 0; Q1 ’24: 0; Q2 ’24: 0; Q3 ’24: 0; Q4 ’24: 0; Q1 ’25: 0; Q2 ’25: 1; Q3 ’25: 1; Q4 ’25: 1; Q1 ’26: 1; Q2 ’26: 1; Q3 ’26: 0

Counts the managers on this site whose 13F for that quarter includes BioNTech.

Who holds it

Each manager’s latest 13F, sorted by how much of their portfolio it is. Changes are against their previous quarter.

Managers holding BioNTech
Dodge & Cox0.2%$342m$342mAdded 0.0%5 qtrs

Download the holders: CSV · JSON · Markdown

Directors buying and selling

Open-market trades by directors, officers and 10% holders over the last 12 months. How this works
From their Form 4 filings with the SEC. Grants, option exercises and shares sold to pay tax are left out.
Insider purchases and sales of BioNTech
Bought or soldFiling
9 Oct 2026Sahin UgurChief Executive Officer▼ Sold36,209$95.37$3.5mForm 4
8 Oct 2026Sahin UgurChief Executive Officer▼ Sold27,000$92.31$2.5mForm 4
7 Oct 2026Sahin UgurChief Executive Officer▼ Sold24,000$95.86$2.3mForm 4
6 Oct 2026Sahin UgurChief Executive Officer▼ Sold21,000$96.81$2.0mForm 4
5 Oct 2026Sahin UgurChief Executive Officer▼ Sold72,000$97.23$7.0mForm 4
2 Oct 2026Sahin UgurChief Executive Officer▼ Sold17,000$96.72$1.6mForm 4
1 Oct 2026Sahin UgurChief Executive Officer▼ Sold17,000$97.46$1.7mForm 4
30 Sep 2026Sahin UgurChief Executive Officer▼ Sold32,000$98.12$3.1mForm 4
29 Sep 2026Sahin UgurChief Executive Officer▼ Sold34,000$98.26$3.3mForm 4
28 Sep 2026Sahin UgurChief Executive Officer▼ Sold34,000$98.47$3.3mForm 4
25 Sep 2026Sahin UgurChief Executive Officer▼ Sold27,000$98.69$2.7mForm 4
24 Sep 2026Sahin UgurChief Executive Officer▼ Sold39,000$98.99$3.9mForm 4
23 Sep 2026Sahin UgurChief Executive Officer▼ Sold30,000$99.40$3.0mForm 4
22 Sep 2026Sahin UgurChief Executive Officer▼ Sold46,000$100.72$4.6mForm 4
21 Sep 2026Sahin UgurChief Executive Officer▼ Sold33,000$97.81$3.2mForm 4
18 Sep 2026Sahin UgurChief Executive Officer▼ Sold30,000$96.22$2.9mForm 4
17 Sep 2026Sahin UgurChief Executive Officer▼ Sold34,000$98.60$3.4mForm 4
16 Sep 2026Sahin UgurChief Executive Officer▼ Sold15,000$96.09$1.4mForm 4
15 Sep 2026Sahin UgurChief Executive Officer▼ Sold34,000$96.49$3.3mForm 4
14 Sep 2026Sahin UgurChief Executive Officer▼ Sold41,000$99.45$4.1mForm 4

About the company

Sector
Health care · Biological Products, (No Diagnostic Substances)
Financial year ends
31 December
Shares outstanding
251m at 27 Mar 2026
SEC filings
Annual reports and other filings on EDGAR

In fund portfolios

US-registered funds run by these managers that hold BioNTech, from their latest N-PORT filings.

Funds holding BioNTech
Dodge & Cox Global Stock FundDodge & Cox0.4%$48.9m30 Jun 2026
Dodge & Cox International Stock FundDodge & Cox0.3%$234m30 Jun 2026